Cubist Pharmaceuticals to Present at May 2009 Investor Conferences

LEXINGTON, Mass.--(Business Wire)--
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Michael Bonney,
President and CEO, will present on Wednesday May 13th at 2 p.m. Eastern Time, at
the Bank of America and Merrill Lynch 2009 Healthcare Conference at The Palace
Hotel, New York City. David McGirr, SVP and CFO, will present on Thursday, May
14th at 10:05 a.m. Central Time, at the R.W. Baird 2009 Growth Stock Conference
being held at the Four Seasons Hotel in Chicago. These presentations will
include discussion of the company`s business activities, financial outlook, and
current news.

Live webcasts of the presentations will be accessible through Cubist`s website
at www.cubist.com in the Investor Relations Conference Calendar section. The
webcasts will be available on Cubist`s website for a period of 30 days after the
presentations.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development, and commercialization of pharmaceutical products that
address unmet medical needs in the acute care environment. In the U.S., Cubist
markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class
of anti-infectives called lipopeptides. In July 2008, Cubist began promoting
MERREM® I.V. (meropenem for injection) in the United States. MERREM is an
established broad spectrum antibiotic developed by AstraZeneca. The Cubist
product pipeline includes ecallantide, a recombinant human protein in Phase 2
clinical trials - CONSERV-1 and the planned CONSERV-2 - for the reductionof
blood loss during cardiothoracic surgery, and two Phase 1 programs that address
unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and
the other for infections caused by multi-drug resistant (MDR) Gram-negative
bacteria. In addition, the Company, in collaboration with Alnylam
Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program
underway in novel treatments for respiratory syncytial virus infections using
Alnylam`s RNA-interference technology. Cubist is headquartered in Lexington, MA.
Additional information can be found at Cubist`s web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of
companies.

Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Corporate Communications
eileen.mcintyre@cubist.com
or
Weber Shandwick
Tara Murphy, 617-520-7045
tmurphy@webershandwick.com

Copyright Business Wire 2009